Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: Voyager Brings Home Pair Of CNS Collaborations

Executive Summary

Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.

You may also be interested in...



Start-Up Quarterly Statistics, Q3 2016

A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.

Denali Builds Neurodegeneration Pipeline Through Discovery, Collaborations And Lots Of Cash

The amount of venture capital that Denali Therapeutics Inc. has raised and the number of collaborations it's negotiated in less than two years is pretty staggering for a startup biopharmaceutical company, not to mention a startup focused on the central nervous system and neurodegeneration.

Deal Watch: Flagship Ventures Doubles Down On Microbiome

Two of the VC's biotechs merged to create an immuno-microbiome company, while Seres is working with Emulate on better tech for microbiome research. UK specialty pharma Martindale acquired small hospital products-focused UK firm Viridian, and Bayer and X-Chem expanded their drug discovery alliance.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC097280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel